General Information of Drug Combination (ID: DCQ7OW0)

Drug Combination Name
Gentamicin Azithromycin
Indication
Disease Entry Status REF
Gonorrhoea Phase 1 [1]
Component Drugs Gentamicin   DMKINJO Azithromycin   DMS6UOE
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Gentamicin
Disease Entry ICD 11 Status REF
Bacteremia 1A73 Approved [2]
Bacterial infection 1A00-1C4Z Approved [3]
Blepharoconjunctivitis N.A. Approved [2]
Cholangitis N.A. Approved [2]
Dacryocystitis N.A. Approved [2]
Demodex blepharitis 1G07 Approved [2]
Folliculitis N.A. Approved [2]
Neonatal sepsis N.A. Approved [2]
Paronychia 1F23.13 Approved [2]
Peritonitis N.A. Approved [2]
Pseudomonas aeruginosa infectious disease N.A. Approved [2]
Gentamicin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial 30S ribosomal RNA (Bact 30S rRNA) TTOVFH2 NOUNIPROTAC Modulator [9]
------------------------------------------------------------------------------------
Gentamicin Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Aminoglycoside O-phosphotransferase (aphA6) DEWPAJD KKA6_ACIBA Metabolism [10]
Aminoglycoside phosphotransferase (aph-Ib) DE5WGIM A0A075C7U3_CAMJU Metabolism [11]
Kanamycin/gentamycin-resistance enzyme (aacA) DECXWN8 J3S7E2_CAMCO Metabolism [11]
Endoglucanase Y (EGY) DE2M583 A0A256VAC0_LACRE Metabolism [12]
Endoglucanase Y (EGY) DE2AZTG A0A256VAC0_LACRE Metabolism [12]
Aminoglycoside 6'-N-acetyltransferase (aacA) DE48UAX C5MQW3_KLEPO Metabolism [13]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Gentamicin Interacts with 53 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Alpha-L-iduronidase (IDUA) OTTQQ7FN IDUA_HUMAN Increases Expression [14]
Tripeptidyl-peptidase 1 (TPP1) OT2LQ771 TPP1_HUMAN Increases Expression [15]
Exocyst complex component 3 (EXOC3) OT8N3306 EXOC3_HUMAN Increases Expression [16]
Slit homolog 1 protein (SLIT1) OT35RBNT SLIT1_HUMAN Decreases Expression [8]
Coagulation factor VIII (F8) OTH6XHDU FA8_HUMAN Increases Expression [17]
Coagulation factor IX (F9) OTT0CX3Q FA9_HUMAN Increases Expression [17]
Cystatin-C (CST3) OTNZ6AO4 CYTC_HUMAN Increases Expression [16]
Pro-epidermal growth factor (EGF) OTANRJ0L EGF_HUMAN Decreases Expression [16]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [18]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [16]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Increases Expression [16]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [7]
Heat shock 70 kDa protein 1A (HSPA1A) OTKGIE76 HS71A_HUMAN Increases Expression [19]
Dystrophin (DMD) OTD21T5J DMD_HUMAN Increases Expression [20]
Xaa-Pro dipeptidase (PEPD) OT3LFY7S PEPD_HUMAN Decreases Activity [21]
Cystic fibrosis transmembrane conductance regulator (CFTR) OT6B22QH CFTR_HUMAN Increases Activity [22]
Aminopeptidase N (ANPEP) OTP3WYFD AMPN_HUMAN Increases Secretion [23]
Methylmalonyl-CoA mutase, mitochondrial (MMUT) OTBBBV70 MUTA_HUMAN Affects Expression [24]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [7]
Endothelin receptor type B (EDNRB) OTLLZV3P EDNRB_HUMAN Increases Expression [8]
Insulin-like growth factor-binding protein 5 (IGFBP5) OTRE5V0C IBP5_HUMAN Decreases Expression [8]
HLA class I histocompatibility antigen, alpha chain F (HLA-F) OT76CM19 HLAF_HUMAN Increases Expression [8]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Expression [16]
Leukemia inhibitory factor receptor (LIFR) OT36W9O5 LIFR_HUMAN Decreases Degradation [25]
ATP-sensitive inward rectifier potassium channel 1 (KCNJ1) OTIXCRI6 KCNJ1_HUMAN Increases Expression [26]
Cytosolic purine 5'-nucleotidase (NT5C2) OTJMF66Z 5NTC_HUMAN Increases Expression [8]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Expression [16]
Potassium voltage-gated channel subfamily KQT member 4 (KCNQ4) OT29B58J KCNQ4_HUMAN Decreases Expression [8]
Beta-2-microglobulin (B2M) OTDWN6NX B2MG_HUMAN Increases Expression [27]
Neutrophil gelatinase-associated lipocalin (LCN2) OTSB42BR NGAL_HUMAN Decreases Secretion [28]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [16]
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Increases Expression [29]
Polycystin-2 (PKD2) OTIXBU8H PKD2_HUMAN Increases Expression [30]
Runt-related transcription factor 3 (RUNX3) OTITK1XD RUNX3_HUMAN Decreases Expression [8]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) OTXEE550 APR_HUMAN Increases Expression [7]
Interleukin-18 (IL18) OTBB2A8O IL18_HUMAN Decreases Expression [16]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Expression [16]
Partitioning defective 3 homolog (PARD3) OTH5BPLO PARD3_HUMAN Decreases Expression [8]
GATOR1 complex protein NPRL2 (NPRL2) OTOB10MO NPRL2_HUMAN Decreases Expression [8]
Hepatitis A virus cellular receptor 1 (HAVCR1) OT184CRZ HAVR1_HUMAN Increases Expression [16]
Rho guanine nucleotide exchange factor 26 (ARHGEF26) OTX0U8PX ARHGQ_HUMAN Increases Expression [8]
G-protein coupled receptor 20 (GPR20) OTPCR8F7 GPR20_HUMAN Increases Expression [8]
Polyadenylate-binding protein-interacting protein 1 (PAIP1) OTL2F5T5 PAIP1_HUMAN Decreases Expression [8]
Large subunit GTPase 1 homolog (LSG1) OTDAXJ9L LSG1_HUMAN Decreases Expression [8]
Glyoxalase domain-containing protein 4 (GLOD4) OTBJKFXA GLOD4_HUMAN Decreases Expression [8]
DNA-directed DNA/RNA polymerase mu (POLM) OT0SRIP4 DPOLM_HUMAN Increases Expression [8]
Ubiquitin-like-conjugating enzyme ATG3 (ATG3) OT28VBVK ATG3_HUMAN Decreases Expression [8]
Phospholipase A2 (PLA2G1B) OT1GG9FK PA21B_HUMAN Increases ADR [31]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1) OT9HYT7A PLCB1_HUMAN Increases ADR [31]
Sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1) OTCJ458Q AT1A1_HUMAN Increases ADR [31]
Solute carrier family 22 member 2 (SLC22A2) OTGFK1AL S22A2_HUMAN Increases Transport [32]
Lysosomal Pro-X carboxypeptidase (PRCP) OTIUY91L PCP_HUMAN Increases ADR [31]
Dipeptidyl aminopeptidase-like protein 6 (DPP6) OTWW3H0K DPP6_HUMAN Increases ADR [31]
------------------------------------------------------------------------------------
⏷ Show the Full List of 53 DOT(s)
Indication(s) of Azithromycin
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [4]
Bronchitis CA20 Approved [5]
Chancroid N.A. Approved [4]
Mycoplasma pneumoniae pneumonia N.A. Approved [4]
Staphylococcus aureus infection N.A. Approved [4]
Streptococcal pneumonia N.A. Approved [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [6]
Pneumonia caused by chlamydia N.A. Investigative [4]

References

1 ClinicalTrials.gov (NCT00926796) Efficacy of Combination Therapies for Gonorrhea Treatment
2 Gentamicin FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2427).
4 Azithromycin FDA Label
5 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 065511.
6 ClinicalTrials.gov (NCT04332107) Azithromycin for COVID-19 Treatment in Outpatients Nationwide. U.S. National Institutes of Health.
7 A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. J Am Soc Nephrol. 2016 Apr;27(4):1015-28. doi: 10.1681/ASN.2015010060. Epub 2015 Aug 10.
8 Effect of nephrotoxicants and hepatotoxicants on gene expression profile in human peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2010 Oct 15;401(2):245-50. doi: 10.1016/j.bbrc.2010.09.039. Epub 2010 Sep 16.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
11 Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
12 Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
13 Detection of multidrug-resistant Enterobacteriaceae isolated from river waters flowing to the Guanabara Bay and from clinical samples of hospitals in Rio de Janeiro, Brazil. Biomedica. 2019 May 1;39(s1):135-149.
14 Alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. J Mol Biol. 2004 Apr 30;338(3):453-62.
15 Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. Eur J Paediatr Neurol. 2001;5 Suppl A:57-62. doi: 10.1053/ejpn.2000.0436.
16 In vitro evaluation of biomarkers of nephrotoxicity through gene expression using gentamicin. J Biochem Mol Toxicol. 2018 Sep;32(9):e22189. doi: 10.1002/jbt.22189. Epub 2018 Jul 10.
17 Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood. 2005 Nov 1;106(9):3043-8. doi: 10.1182/blood-2005-03-1307. Epub 2005 Jul 28.
18 Gentamicin suppresses endotoxin-driven TNF-alpha production in human and mouse proximal tubule cells. Am J Physiol Renal Physiol. 2007 Oct;293(4):F1373-80. doi: 10.1152/ajprenal.00333.2007. Epub 2007 Aug 15.
19 Increased expression of heat shock protein (HSP)72 in a human proximal tubular cell line (HK-2) with gentamicin-induced injury. J Toxicol Sci. 2006 Feb;31(1):61-70. doi: 10.2131/jts.31.61.
20 Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. 2003 May;22(1):15-21.
21 Melanin potentiates gentamicin-induced inhibition of collagen biosynthesis in human skin fibroblasts. Eur J Pharmacol. 2002 Jun 20;446(1-3):7-13. doi: 10.1016/s0014-2999(02)01793-4.
22 Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in cystic fibrosis bile ductular cells. Hepatology. 2002 Jan;35(1):95-104. doi: 10.1053/jhep.2002.30423.
23 Investigations on the potential nephrotoxicity of cefazedone and gentamicin and of their combination, in comparison with the combination of cefazolin and cephalothin with gentamicin. Arzneimittelforschung. 1979;29(2a):449-52.
24 Stop codon read-through of a methylmalonic aciduria mutation. Mol Genet Metab. 2009 Aug;97(4):244-9. doi: 10.1016/j.ymgme.2009.04.004. Epub 2009 Apr 12.
25 In vitro readthrough of termination codons by gentamycin in the Stve-Wiedemann Syndrome. Eur J Hum Genet. 2010 Jan;18(1):130-2. doi: 10.1038/ejhg.2009.122.
26 Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int. 2003 Sep;64(3):923-32. doi: 10.1046/j.1523-1755.2003.00153.x.
27 The absence of nephrotoxicity and differential nephrotoxicity between tobramycin and gentamicin. South Med J. 1990 Oct;83(10):1149-52. doi: 10.1097/00007611-199010000-00008.
28 Neutrophil gelatinase-associated lipocalin production negatively correlates with HK-2 cell impairment: Evaluation of NGAL as a marker of toxicity in HK-2 cells. Toxicol In Vitro. 2017 Mar;39:52-57. doi: 10.1016/j.tiv.2016.11.012. Epub 2016 Nov 22.
29 Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15676-81. doi: 10.1073/pnas.0405155101. Epub 2004 Oct 21.
30 Deficiency of polycystin-2 reduces Ca2+ channel activity and cell proliferation in ADPKD lymphoblastoid cells. FASEB J. 2004 May;18(7):884-6. doi: 10.1096/fj.03-0687fje. Epub 2004 Mar 4.
31 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
32 Organic Cation Transporter 2 Overexpression May Confer an Increased Risk of Gentamicin-Induced Nephrotoxicity. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5573-80. doi: 10.1128/AAC.00907-16. Print 2016 Sep.